Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710410 | 0.90 | GLS (0.52) | GLSCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL29910448 | 0.90 | GLS (0.52) | GLSCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13236926 | 0.90 | GLS (0.54) | GLSCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16855800 | 0.89 | GLS (0.53) | GLSCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL24732680 | 0.89 | PRMT6 (0.54) | GLSCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2194827 | 0.87 | KDM1A (0.57) | GLSCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8540779 | 0.87 | ALDH1A1 (0.63) | GLSCHRM2CHRM3ALDH1A1HTT | |
| SCHEMBL4938599 | 0.87 | VEGFA (0.56) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL4709921 | 0.86 | GLS (0.52) | GLSCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14987039 | 0.86 | GLS (0.56) | GLSCHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017195069-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| CN-1285594-C | Diazacycloalkanes as oxytocin agonists | FERRING BV (NL) | 2006-11-22 | — | — | CN | disclosed |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
| CN-1751050-A | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING BV (NL) | 2006-03-22 | — | — | CN | disclosed |
| EP-1592693-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | Ferring B.V. (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | FEERING B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| CN-1543467-A | Diazacycloalkanes as oxytocin agonists | — | 2004-11-03 | — | — | CN | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| EP-1421087-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | OXTR, GNRHR, KISS1R | GLS 1254/4885CHRM2 408/4885CHRM4 377/4885 |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | GLS 2018/4885CHRM2 1465/4885CHRM4 1602/4885 |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | GLS 1430/4885CHRM2 811/4885CHRM4 1281/4885 |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | GLS 2018/4885CHRM2 1465/4885CHRM4 1602/4885 |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | GLS 616/4885CHRM2 3276/4885CHRM4 2363/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | GLS 616/4885CHRM2 3276/4885CHRM4 2363/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | GLS 1430/4885CHRM2 811/4885CHRM4 1281/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | GLS 616/4885CHRM2 3276/4885CHRM4 2363/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | GLS 616/4885CHRM2 3276/4885CHRM4 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.